Antioxidants and atherosclerotic heart disease

New England Journal of Medicine

Volumn 337, Issue 6, 1997, Pages 408-416

  Diaz, Marco N ^a   Frei, Balz ^a   Vita, Joseph A ^a   Keaney Jr , John F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; LOW DENSITY LIPOPROTEIN; PLACEBO;

ANGINA PECTORIS; ANGIOGRAPHY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; DIETARY INTAKE; FOLLOW UP; HEART DISEASE; HUMAN; HYPOTHESIS; LIPID PEROXIDATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIOXIDANTS; ARTERIES; CORONARY ARTERIOSCLEROSIS; HUMANS; LIPOPROTEINS, LDL; MONOCYTES; NITRIC OXIDE; OXIDATION-REDUCTION; PLATELET ACTIVATION; VITAMINS;

EID: 0030839661     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199708073370607     Document Type: Review

References (76)

1. Verlangieri AJ, Kapeghian JC, el-Dean S, Bush M. Fruit and vegetable consumption and cardiovascular disease mortality. Med Hypotheses 1985; 16:7-15.
2. Gey KF, Puska P. Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann N Y Acad Sci 1989;570:268-82.
3. Riemersma RA, Wood DA, Macintyre CCH, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E, and carotene. Lancet 1991;337:1-5.
4. Ramirez J, Flowers NC. Leukocyte ascorbic acid and its relationship to coronary heart disease in man. Am J Clin Nutr 1980;33:2079-87.
5. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9.
6. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
7. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992;3: 194-202.
8. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr 1996;64:190-6.
9. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
10. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334: 1145-9.
11. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
12. Gaziano JM, Manson JE, Hennekens CH. Natural antioxidants and cardiovascular disease: observational epidemiologic studies and randomized trials. In: Frei B, ed. Natural antioxidants in human health and disease. San Diego, Calif.: Academic Press, 1994:387-409.
13. Riemersma RA, Wood DA, Macintyre CCH, Elton RA, Gey KF, Oliver MF. Low plasma vitamins E and C: increased risk of angina in Scottish men. Ann N Y Acad Sci 1989;570:291-5.
14. Navab M, Berliner JA, Watson AD, et al. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vase Biol 1996;16:831-42.
15. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8.
16. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphatc. J Clin Invest 1993;92:471-8.
17. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoproten previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 1981;78:6499-503.
18. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988;85:2805-9.
19. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991;90:119-26.
20. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM. The pathogenesis of atherosclerosis: an overview. Clin Cardiol 1991;14:Suppl I:I1-I16.
21. Cathcart MK, Morel DW, Chisolm GM III. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol 1985;38:341-50.
22. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 1989;86:1372-6.
23. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
24. Salonen T, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339: 883-7.
25. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995;95:2611-9.
26. Reaven PD, Parthasarathy S, Beltz WF, Witztum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992;12:318-24.
27. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725-9.
28. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987; 84:5928-31.
29. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994;94:155-64.
30. Sparrow CP, Doebber TW, Olszewski J, et al. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′ diphenyl-phenylenediamine. J Clin Invest 1992;89:1885-91.
31. Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992;94:153-9.
32. Parker RA, Sabrah T, Cap M, Gill BT. Relation of vascular oxidative stress, α-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler Thromb Vase Biol 1995;15:349-58.
33. Keaney JF Jr, Frei B. Antioxidant protection of low-density lipoprotcin and its role in the prevention of atherosclerotic vascular disease. In: Frei B, ed. Natural antioxidants in human health and disease. San Diego, Calif: Academic Press, 1994:303-52.
34. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans: protection of LDL by vitamin E but not beta carotene. Arterioscler Thromb 1993;13:590-600.
35. Gaziano JM, Hatta A, Flynn M, et al. Supplementation with beta-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. Atherosclerosis 1995;112:187-95.
36. Retsky KL, Freeman MW, Frei B. Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification: anti-rather than prooxidant activity of vitamin C in the presence of transition metal ions. J Biol Chem 1993;268:1304-9.
37. Stary HC. Evolution of atherosclerotic plaques in the coronary arteries of young adults. Arteriosclerosis 1983;3:471. abstract.
38. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995;273:1849-54.
39. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83.
40. Walldius G, Regnstrom J, Nilsson J, et al. The role of lipids and antioxidative factors for development of atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1993,71: 15B-19B.
41. 2b, by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia: a Probucol Quantitative Regression Swedish Trial (PQRST) report. Arterioscler Thromb Vasc Biol 1995;15:1049-56.
42. Shaish A, Daugherty A, O'Sullivan F, Schonfeld G, Heinecke JW. Betacarotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest 1995;96:2075-82.
43. Kleinveld HA, Hak-Lemmers HL, Hectors MP, de Fouw NJ, Demacker PN, Stalenhoef AE. Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 1995;15:290-7.
44. Keaney JF Jr, Gaziano JM, Xu A, et al. Low-dose α-tocopherol improves and high-dose α-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994;93:844-51.
45. Keaney JF Jr, Xu A, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest 1995;95:2520-9.
46. Levinc GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
47. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983;24: 1070-6.
48. Hughes H, Mathews B, Lenz ML, Guyton JR. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler Thromb 1994;14:1177-85.
49. Belcher JD, Balla J, Balla G, et al. Vitamin E, LDL, and endothelium: brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. Arterioscler Thromb 1993;13:1779-89.
50. Friedman M, van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol 1966;48:19-44.
51. Falk E. Why do plaques rupture? Circulation 1992;86:Suppl III: III-30-III-42.
52. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-8.
53. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992;89:10-8.
54. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-2.
55. Kugiyama K, Ohgushi M, Sugiyama S, et al. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells bv a pathway involving protein kinase C activation. Circ Res 1992;71: 1422-8. [Erratum, Circ Res 1993;72:723.]
56. Plane F, Jacobs M, McManus D, Bruckdorfer KR. Probucol and other antioxidants prevent the inhibition of endothelium dependent relaxation by low density lipoproteins. Atherosclerosis 1993;103:73-9
57. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-50.
58. Keaney JF Jr, Gaziano JM, Xu A, et al. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci U S A 1993;90:11880-4.
59. Andersson TLG, Matz J, Ferns GAA, Änggård EE. Vitamin E reverses cholesterol induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis 1994;111:39-45.
60. Steward-Lee AL, Forster LA, Nourooz Zadch J, Ferns GAA, Änggård EE. Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol fed rabbits. Arterioscler Thromb 1994;14: 494-9.
61. Simon BC, Haudenschild CC, Cohen RA. Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol. J Cardiovasc Pharmacol 1993;21:893-901.
62. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases cndothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
63. Keaney JF Jr, Guo Y, Cunningham D, Shwaery GT, Xu A, Vita JA. Vascular incorporation of α-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest 1996;98:386-94.
64. Celermajer DS, Sorensen KE, Gooch VM, et al. Non invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
65. Andersen TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41.
66. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107-13.
67. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995;748:501-7.
68. Collins T. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion. Lab Invest 1993;68:499-508.
69. Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 1994;94:592-600.
70. Devaraj S, Li D, Jialal I. The effects of alpha tocopherol supplementation on monocyte function: decreased lipid oxidation, interleukin 1β secretion, and monocyte adhesion to endothelium. J Clin Invest 1996;98: 756-63.
71. Kuzuya M, Naito M, Funaki C, Hayashi T, Asai K, Kuzuya F. Probucol prevents oxidative injury to endothelial cells. J Lipid Res 1991;32: 197-204.
72. Reid VC, Mitchinson MJ. Toxicity of oxidised low density lipoprotein towards mouse peritoneal macrophages in vitro. Atherosclerosis 1993;98: 17-24.
73. Freedman JE, Farhat JH, Loscalzo J, Keaney JF Jr. α-Tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996;94:2434-40.
74. Boscoboinik D, Szewczyk A, Azzi A. Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity. Arch Biochem Biophys 1991;286:264-9.
75. Tardif J-C, Côté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-72.
76. O'Keefe JH Jr, Stone GW, McCallister BD Jr, et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649-52.